I-Chondloitin sulfate yokwelashwa kwesifo senhliziyo ye-coronary, isifo samathambo kanye nokuphulukiswa kwamanxeba e-corneal purnity 98%

Ukufanisa

I-Chondloititulfate (CS) i-mucopololysaccharide ekhishwe futhi ihlanzwe kusuka ezifuzweni ze-cartilage zezilwane. I-Chondloitin Sulfate inezakhiwo ezahlukahlukene ezinjenge-a, c, d, e, h no-K. Chondroitin sulfate emvelweni, ithambo le-Throat, amathambo ama-36 (amathambo, isikhumba, isikhumba, futhi. Okuqukethwe kwe-cartilage yezinhlanzi kucebile kakhulu, njenge-50% kuya ku-60% ku-shark ithambo, futhi kuncane kakhulu ngezicubu ezithintekayo.

Kulesi sifo se-coronary atherosurerotic, ama-cholesterol ama-cholesterol, i-arteriosterosis, i-angina pectoris, i-myocardial ischemia, infardial inchemia, njll. Ezigulini ezinesifo senhliziyo.

Isenzo samakhemisi

I-Rapamycin (RapA) inemiphumela emibi efanayo ku-FK506. Esikhathini esikhulu sezilingo zomtholampilo, imiphumela yayo emibi yatholakala ukuthi ithembeke umthamo futhi iguqulwe, futhi i-rapA ngemithamo yokwelapha ayitholakalanga ukuthi ine-nephrotoxicia ebalulekile futhi akukho gingival hyperplasia. Imiphumela enobuthi enobuthi kanye nemibi ifaka: ikhanda, isicanucanu, isiyezi, ama-nosebleed, nobuhlungu obuhlangene. Ukuhlukunyezwa kwelebhu kufaka phakathi: I-Thrombopenia, i-hemoglobin ephansi, i-hypercriglytolemia, i-hyperglytemia, i-hyperglycemia, i-hypomagtemia, stymema, stymema muva nje kubikwa ngeRapa Ukuphatha, kanye nembangela yamazinga aphansi we-plasma phosphate kucatshangwa ukuthi kudluliswa isikhathi eside phosphate kusuka ezinsolweni ezitshaliwe yi-rapa-based immunosuppy therapy. Njengamanye ama-Immunosuppressants, iRapa inethuba elikhulayo lokutheleleka, ngokuthambekela okubikiwe ukwandisa inyumoniya ikakhulukazi, kodwa ukwenzeka kwezinye izifo ezinamathuba akwehlukile kakhulu ku-CSA.

Imiphumela yobuthi

I-Chondloitin Sulfate ikhona kabanzi ezicubu ze-cartilage yabantu. Ukulungiswa kwezokwelapha ikakhulukazi kuqukethe ama-isomers amabili we-chondoroitin sulfate a ne-chondroitin sulfate C, kanye nokuqukethwe kwe-chondoitin sulfate ekuhlolweni kwezilwane ezahlukahlukene neminyaka yehlukile. Imiphumela yayo yemithi yayo imi ngalendlela elandelayo: I-Chondloitin Sulfate ingasusa ama-lipid nama-lipoprotel egazini, igweme futhi yandise izinga lokuguqulwa kwama-lipid nama-acid anamafutha kumaseli. I-Chondloitin sulfate ingavimbela ngempumelelo futhi iphathe isifo senhliziyo. Inobuthi be-anti-atherossteosis kanye nemiphumela yokwakheka kwe-anti-atherogenic ye-anti-atherogenic kumamodeli wokuhlola we-artterineral; kwandisa amagatsha e-coronary noma ukusakazwa okuningana kwe-atherossteosis, futhi kungasheshisa i-arteriosteosis yokuhlola noma i-embolism. Ukuphulukisa, ukuvuselelwa kabusha kanye nokulungiswa kwe-MyOCardial Necrosis noma ukuwohloka. Kungakhuphula i-biosynthesis ye-cells Messenger rionucleic acid (Mrna) kanye ne-deoxyribonucleic acid (DNA) futhi inomphumela wokukhuthaza imetabolism yeselula. Umsebenzi ophansi we-anticoagulant. I-Chondloitin Sulfate inomphumela olinganiselayo we-anticoagulant, futhi i-1 mg ngayinye ye-chondoitin sulfate a ilingana nomsebenzi we-anticoagulant we-0.45u ye-herparin. Lo msebenzi we-anticouagulant awuxhomekile kwi-antithrombin III ukuze udlale indima yawo, kungawusebenzisa umsebenzi we-anticogeagulant ngohlelo lwe-fibrinogen. I-Chondloitin sulfate nayo inokulwa nokuvuvukala, ukushesha ukuphulukiswa kwezilonda nemiphumela ye-anti-futus.